Latest Pharma Insights
Beiersdorf Sees Early Gains In Nivea Strategy, Despite Tough Q1
Beiersdorf AG’ first quarter organic sales slipped 7% on weakness for its Nivea skin care, but the firm’s rebalancing strategy to revive the brand is starting to pay off, says CEO Vincent Warnery.
HBW Insight - April 22, 2026
Beiersdorf AG’ first quarter organic sales slipped 7% on weakness for its Nivea skin care, but the firm’s rebalancing strategy to revive the brand is starting to pay off, says CEO Vincent Warnery.
HBW Insight - April 22, 2026
Idvynso Approval Gives Merck A Competitor In Once-Daily Oral HIV Market
With FDA approval of the islatravir and doravirine combo for HIV, Merck hopes it has a full treatment regimen to challenge Gilead and ViiV Healthcare’s leadership in the space.
Scrip - April 22, 2026
With FDA approval of the islatravir and doravirine combo for HIV, Merck hopes it has a full treatment regimen to challenge Gilead and ViiV Healthcare’s leadership in the space.
Scrip - April 22, 2026
Expanding OTC Choices In US: Confuse Consumers While Increasing Out-Of-Pocket Costs?
In comments to FDA docket, Conservative Political Action Coalition states suspicion and criticism of pricing practices common for drugs becoming available OTC after being Rx-only while pharmacists groups predict consumer confusion with more OTC choices.
HBW Insight - April 22, 2026
In comments to FDA docket, Conservative Political Action Coalition states suspicion and criticism of pricing practices common for drugs becoming available OTC after being Rx-only while pharmacists groups predict consumer confusion with more OTC choices.
HBW Insight - April 22, 2026
MedCon Day 1: MDUFA Negotiators Tout ‘Historic Timeline’ In Reaching Agreement On User Fees
At MedCon 2026 in Columbus, Ohio, MDMA’s Mark Leahey credited the FDA’s transparency for the swift agreement on user fee terms. The FDA’s Barb Marsden said the agency is also meeting its current MDUFA goals.
Medtech Insight - April 22, 2026
At MedCon 2026 in Columbus, Ohio, MDMA’s Mark Leahey credited the FDA’s transparency for the swift agreement on user fee terms. The FDA’s Barb Marsden said the agency is also meeting its current MDUFA goals.
Medtech Insight - April 22, 2026
BALANCE Model Delay May Lead To Revisions, Higher Near-Term Medicare Costs
Will CMS wait for even lower obesity drug prices before implementing a long-term solution in Medicare?
Generics Bulletin - April 22, 2026
Will CMS wait for even lower obesity drug prices before implementing a long-term solution in Medicare?
Generics Bulletin - April 22, 2026
Feeding Pump That Grew From A Father’s Mission Receives FDA Clearance
Luminoah’s compact, smart enteral feeding pump has won FDA clearance as CEO Neal Piper, who founded the company after his son was diagnosed with a rare brain cancer at age 3, prepares to launch it at three health systems.
Medtech Insight - April 22, 2026
Luminoah’s compact, smart enteral feeding pump has won FDA clearance as CEO Neal Piper, who founded the company after his son was diagnosed with a rare brain cancer at age 3, prepares to launch it at three health systems.
Medtech Insight - April 22, 2026
PureTech’s Gallop Maintains Steady Gait In MDS After Strong Showing For LYT-200
The hub-and-spoke biotech’s Gallop Oncology subsidiary will prioritize high-risk myelodysplastic syndrome given the greater clinical need.
Scrip - April 22, 2026
The hub-and-spoke biotech’s Gallop Oncology subsidiary will prioritize high-risk myelodysplastic syndrome given the greater clinical need.
Scrip - April 22, 2026
Finance Watch: First Tracks Completes Spinout From AnaptysBio
Public Company Edition: AnaptysBio is managing Jemperli and imsidolimab royalties from GSK and Vanda, respectively, while First Tracks is advancing antibody drugs for autoimmune diseases. Also, the follow-on party continues, with Nektar, Trevi, MeiraGTx and Prelude pricing new offerings.
Scrip - April 22, 2026
Public Company Edition: AnaptysBio is managing Jemperli and imsidolimab royalties from GSK and Vanda, respectively, while First Tracks is advancing antibody drugs for autoimmune diseases. Also, the follow-on party continues, with Nektar, Trevi, MeiraGTx and Prelude pricing new offerings.
Scrip - April 22, 2026
Danaher Signals M&A Capacity For More Deals Even As $9.9Bn Masimo Integration Begins
Danaher is keeping its M&A engine running even while integrating the $9.9bn acquisition of Masimo. CEO Rainer Blair told analysts improving valuations and a strong deal pipeline position the company to pursue further acquisitions across its diagnostics, life sciences and bioprocessing portfolio.
Medtech Insight - April 22, 2026
Danaher is keeping its M&A engine running even while integrating the $9.9bn acquisition of Masimo. CEO Rainer Blair told analysts improving valuations and a strong deal pipeline position the company to pursue further acquisitions across its diagnostics, life sciences and bioprocessing portfolio.
Medtech Insight - April 22, 2026
Intuitive Raises 2026 Growth Outlook As da Vinci 5 Drives Utilization Growth
Intuitive Surgical outlined a layered artificial intelligence strategy for surgical robotics, built on surgical video, robotic data streams and integrated electronic medical records.
Medtech Insight - April 22, 2026
Intuitive Surgical outlined a layered artificial intelligence strategy for surgical robotics, built on surgical video, robotic data streams and integrated electronic medical records.
Medtech Insight - April 22, 2026
A Single Dose Changes The Conversation: CAR-T Arrives In Autoimmune Neurology
Kyverna's pivotal stiff person syndrome data and early myasthenia gravis results, alongside Cabaletta Bio's first gMG readout, mark a turning point for cell therapy in autoimmune disease.
Scrip - April 22, 2026
Kyverna's pivotal stiff person syndrome data and early myasthenia gravis results, alongside Cabaletta Bio's first gMG readout, mark a turning point for cell therapy in autoimmune disease.
Scrip - April 22, 2026
Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026
Clinical Supply Flexibility Where Biotech Programs Need It Most
Clinical supply demands don’t stand still—and neither should your strategy. This infographic highlights how flexible, scalable support can adapt alongside your program from early development through commercialization.
Scrip - April 22, 2026
Clinical supply demands don’t stand still—and neither should your strategy. This infographic highlights how flexible, scalable support can adapt alongside your program from early development through commercialization.
Scrip - April 22, 2026
Early-Phase Injectable Formulation Development
Early-stage injectable formulation comes with complex challenges—from solubility to stability to scalability. This white paper explores practical strategies to help you navigate these hurdles with confidence.
Scrip - April 22, 2026
Early-stage injectable formulation comes with complex challenges—from solubility to stability to scalability. This white paper explores practical strategies to help you navigate these hurdles with confidence.
Scrip - April 22, 2026
Accelerator™ Drug Development: Streamlining Preclinical Pathways for a Fast Transition to First-in-H
Explore how Accelerator™ drug development is streamlining preclinical pathways to enable faster, efficient transitions to first-in-human trials and accelerate innovation in pharma.
Scrip - April 22, 2026
Explore how Accelerator™ drug development is streamlining preclinical pathways to enable faster, efficient transitions to first-in-human trials and accelerate innovation in pharma.
Scrip - April 22, 2026
Scaling Biologics: From Late-Stage Development to Commercialization
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Guided by Vision: Redefining OSD Development Through Foresight and Innovation
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Reducing Uncertainty in Early Oral Drug Development: Decisions That Benefit From Predictive Insights
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
How Not To Get ‘Ghosted’ By Pharma And Other Biotech Partnering Tips
Big pharma BD executives at the BioTrinity meeting discussed how they deal with floods of biotech enquiries, and offered key do’s and don’ts for potential partners.
Scrip - April 22, 2026
Big pharma BD executives at the BioTrinity meeting discussed how they deal with floods of biotech enquiries, and offered key do’s and don’ts for potential partners.
Scrip - April 22, 2026
Amneal’s Bevacizumab Biosimilar Brochure Rebuked By FDA’s OPDP
A brochure for Amneal’s Alymsys biosimilar bevacizumab rival to Avastin has caught the attention of the US Food and Drug Administration’s Office of Prescription Drug Promotion.
Generics Bulletin - April 22, 2026
A brochure for Amneal’s Alymsys biosimilar bevacizumab rival to Avastin has caught the attention of the US Food and Drug Administration’s Office of Prescription Drug Promotion.
Generics Bulletin - April 22, 2026
Steep UK Generic Price Rises Continue In March
While not quite as pronounced as the increases seen in February, the latest UK generic price rises show a continuing trend for multiple molecules to more than double in price.
Generics Bulletin - April 22, 2026
While not quite as pronounced as the increases seen in February, the latest UK generic price rises show a continuing trend for multiple molecules to more than double in price.
Generics Bulletin - April 22, 2026
Pharma’s Pipeline Size Dipped In 2025
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026
The 10-80-10 Investment Rule: Preparation Is All
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026
The Generics Bulletin Podcast: Green Regulations With Medicines for Europe’s Adrian van den Hoven
Generics Bulletin senior reporter Urt? Fultinavi?i?t? speaks to Medicines for Europe’s director general Adrian van den Hoven about pertinent environmental regulation changes in the region.
Generics Bulletin - April 22, 2026
Generics Bulletin senior reporter Urt? Fultinavi?i?t? speaks to Medicines for Europe’s director general Adrian van den Hoven about pertinent environmental regulation changes in the region.
Generics Bulletin - April 22, 2026
‘Incomprehensible’ - French CBD Association Slams Sudden Clamp Down
France plans to sharply tighten controls on CBD supplements, drawing criticism from industry group UIVEC, which says the move amounts to a de facto ban and risks undermining compliant operators while missing wider public?health risks.
HBW Insight - April 22, 2026
France plans to sharply tighten controls on CBD supplements, drawing criticism from industry group UIVEC, which says the move amounts to a de facto ban and risks undermining compliant operators while missing wider public?health risks.
HBW Insight - April 22, 2026
EU Parliament Grants Industry Wins, Rejects Some Demands In Omnibus Proposal
European Parliament committees reach an agreement on the European Commission’s ‘omnibus’ chemicals proposal with a report that gives industry some of what it wanted, but denies it on several key points.
HBW Insight - April 22, 2026
European Parliament committees reach an agreement on the European Commission’s ‘omnibus’ chemicals proposal with a report that gives industry some of what it wanted, but denies it on several key points.
HBW Insight - April 22, 2026
Roche Upbeat On Fenebrutinib Filing Prospects Despite Safety Questions
The company’s chief medical officer said he saw no ‘stumbling blocks’ for the potential first-in-class BTK inhibitor in multiple sclerosis, although safety questions will likely persist.
Scrip - April 22, 2026
The company’s chief medical officer said he saw no ‘stumbling blocks’ for the potential first-in-class BTK inhibitor in multiple sclerosis, although safety questions will likely persist.
Scrip - April 22, 2026
Idvynso Approval Gives Merck A Competitor In Once-Daily Oral HIV Market
With FDA approval of the islatravir and doravirine combo for HIV, Merck hopes it has a full treatment regimen to challenge Gilead and ViiV Healthcare’s leadership in the space.
Scrip - April 22, 2026
With FDA approval of the islatravir and doravirine combo for HIV, Merck hopes it has a full treatment regimen to challenge Gilead and ViiV Healthcare’s leadership in the space.
Scrip - April 22, 2026
PureTech’s Gallop Maintains Steady Gait In MDS After Strong Showing For LYT-200
The hub-and-spoke biotech’s Gallop Oncology subsidiary will prioritize high-risk myelodysplastic syndrome given the greater clinical need.
Scrip - April 22, 2026
The hub-and-spoke biotech’s Gallop Oncology subsidiary will prioritize high-risk myelodysplastic syndrome given the greater clinical need.
Scrip - April 22, 2026
Finance Watch: First Tracks Completes Spinout From AnaptysBio
Public Company Edition: AnaptysBio is managing Jemperli and imsidolimab royalties from GSK and Vanda, respectively, while First Tracks is advancing antibody drugs for autoimmune diseases. Also, the follow-on party continues, with Nektar, Trevi, MeiraGTx and Prelude pricing new offerings.
Scrip - April 22, 2026
Public Company Edition: AnaptysBio is managing Jemperli and imsidolimab royalties from GSK and Vanda, respectively, while First Tracks is advancing antibody drugs for autoimmune diseases. Also, the follow-on party continues, with Nektar, Trevi, MeiraGTx and Prelude pricing new offerings.
Scrip - April 22, 2026
A Single Dose Changes The Conversation: CAR-T Arrives In Autoimmune Neurology
Kyverna's pivotal stiff person syndrome data and early myasthenia gravis results, alongside Cabaletta Bio's first gMG readout, mark a turning point for cell therapy in autoimmune disease.
Scrip - April 22, 2026
Kyverna's pivotal stiff person syndrome data and early myasthenia gravis results, alongside Cabaletta Bio's first gMG readout, mark a turning point for cell therapy in autoimmune disease.
Scrip - April 22, 2026
Clinical Supply Flexibility Where Biotech Programs Need It Most
Clinical supply demands don’t stand still—and neither should your strategy. This infographic highlights how flexible, scalable support can adapt alongside your program from early development through commercialization.
Scrip - April 22, 2026
Clinical supply demands don’t stand still—and neither should your strategy. This infographic highlights how flexible, scalable support can adapt alongside your program from early development through commercialization.
Scrip - April 22, 2026
Early-Phase Injectable Formulation Development
Early-stage injectable formulation comes with complex challenges—from solubility to stability to scalability. This white paper explores practical strategies to help you navigate these hurdles with confidence.
Scrip - April 22, 2026
Early-stage injectable formulation comes with complex challenges—from solubility to stability to scalability. This white paper explores practical strategies to help you navigate these hurdles with confidence.
Scrip - April 22, 2026
Accelerator™ Drug Development: Streamlining Preclinical Pathways for a Fast Transition to First-in-H
Explore how Accelerator™ drug development is streamlining preclinical pathways to enable faster, efficient transitions to first-in-human trials and accelerate innovation in pharma.
Scrip - April 22, 2026
Explore how Accelerator™ drug development is streamlining preclinical pathways to enable faster, efficient transitions to first-in-human trials and accelerate innovation in pharma.
Scrip - April 22, 2026
Scaling Biologics: From Late-Stage Development to Commercialization
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Guided by Vision: Redefining OSD Development Through Foresight and Innovation
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Reducing Uncertainty in Early Oral Drug Development: Decisions That Benefit From Predictive Insights
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
Successful oral solid dose (OSD) development starts with a clear vision—and the ability to act on it. This white paper explores how forward-thinking strategies can help anticipate challenges, reduce risk, and drive better outcomes.
Scrip - April 22, 2026
How Not To Get ‘Ghosted’ By Pharma And Other Biotech Partnering Tips
Big pharma BD executives at the BioTrinity meeting discussed how they deal with floods of biotech enquiries, and offered key do’s and don’ts for potential partners.
Scrip - April 22, 2026
Big pharma BD executives at the BioTrinity meeting discussed how they deal with floods of biotech enquiries, and offered key do’s and don’ts for potential partners.
Scrip - April 22, 2026
Roche Upbeat On Fenebrutinib Filing Prospects Despite Safety Questions
The company’s chief medical officer said he saw no ‘stumbling blocks’ for the potential first-in-class BTK inhibitor in multiple sclerosis, although safety questions will likely persist.
Scrip - April 22, 2026
The company’s chief medical officer said he saw no ‘stumbling blocks’ for the potential first-in-class BTK inhibitor in multiple sclerosis, although safety questions will likely persist.
Scrip - April 22, 2026
MedCon Day 1: MDUFA Negotiators Tout ‘Historic Timeline’ In Reaching Agreement On User Fees
At MedCon 2026 in Columbus, Ohio, MDMA’s Mark Leahey credited the FDA’s transparency for the swift agreement on user fee terms. The FDA’s Barb Marsden said the agency is also meeting its current MDUFA goals.
Medtech Insight - April 22, 2026
At MedCon 2026 in Columbus, Ohio, MDMA’s Mark Leahey credited the FDA’s transparency for the swift agreement on user fee terms. The FDA’s Barb Marsden said the agency is also meeting its current MDUFA goals.
Medtech Insight - April 22, 2026
Feeding Pump That Grew From A Father’s Mission Receives FDA Clearance
Luminoah’s compact, smart enteral feeding pump has won FDA clearance as CEO Neal Piper, who founded the company after his son was diagnosed with a rare brain cancer at age 3, prepares to launch it at three health systems.
Medtech Insight - April 22, 2026
Luminoah’s compact, smart enteral feeding pump has won FDA clearance as CEO Neal Piper, who founded the company after his son was diagnosed with a rare brain cancer at age 3, prepares to launch it at three health systems.
Medtech Insight - April 22, 2026
Danaher Signals M&A Capacity For More Deals Even As $9.9Bn Masimo Integration Begins
Danaher is keeping its M&A engine running even while integrating the $9.9bn acquisition of Masimo. CEO Rainer Blair told analysts improving valuations and a strong deal pipeline position the company to pursue further acquisitions across its diagnostics, life sciences and bioprocessing portfolio.
Medtech Insight - April 22, 2026
Danaher is keeping its M&A engine running even while integrating the $9.9bn acquisition of Masimo. CEO Rainer Blair told analysts improving valuations and a strong deal pipeline position the company to pursue further acquisitions across its diagnostics, life sciences and bioprocessing portfolio.
Medtech Insight - April 22, 2026
Intuitive Raises 2026 Growth Outlook As da Vinci 5 Drives Utilization Growth
Intuitive Surgical outlined a layered artificial intelligence strategy for surgical robotics, built on surgical video, robotic data streams and integrated electronic medical records.
Medtech Insight - April 22, 2026
Intuitive Surgical outlined a layered artificial intelligence strategy for surgical robotics, built on surgical video, robotic data streams and integrated electronic medical records.
Medtech Insight - April 22, 2026
Beiersdorf Sees Early Gains In Nivea Strategy, Despite Tough Q1
Beiersdorf AG’ first quarter organic sales slipped 7% on weakness for its Nivea skin care, but the firm’s rebalancing strategy to revive the brand is starting to pay off, says CEO Vincent Warnery.
HBW Insight - April 22, 2026
Beiersdorf AG’ first quarter organic sales slipped 7% on weakness for its Nivea skin care, but the firm’s rebalancing strategy to revive the brand is starting to pay off, says CEO Vincent Warnery.
HBW Insight - April 22, 2026
Expanding OTC Choices In US: Confuse Consumers While Increasing Out-Of-Pocket Costs?
In comments to FDA docket, Conservative Political Action Coalition states suspicion and criticism of pricing practices common for drugs becoming available OTC after being Rx-only while pharmacists groups predict consumer confusion with more OTC choices.
HBW Insight - April 22, 2026
In comments to FDA docket, Conservative Political Action Coalition states suspicion and criticism of pricing practices common for drugs becoming available OTC after being Rx-only while pharmacists groups predict consumer confusion with more OTC choices.
HBW Insight - April 22, 2026
‘Incomprehensible’ - French CBD Association Slams Sudden Clamp Down
France plans to sharply tighten controls on CBD supplements, drawing criticism from industry group UIVEC, which says the move amounts to a de facto ban and risks undermining compliant operators while missing wider public?health risks.
HBW Insight - April 22, 2026
France plans to sharply tighten controls on CBD supplements, drawing criticism from industry group UIVEC, which says the move amounts to a de facto ban and risks undermining compliant operators while missing wider public?health risks.
HBW Insight - April 22, 2026
EU Parliament Grants Industry Wins, Rejects Some Demands In Omnibus Proposal
European Parliament committees reach an agreement on the European Commission’s ‘omnibus’ chemicals proposal with a report that gives industry some of what it wanted, but denies it on several key points.
HBW Insight - April 22, 2026
European Parliament committees reach an agreement on the European Commission’s ‘omnibus’ chemicals proposal with a report that gives industry some of what it wanted, but denies it on several key points.
HBW Insight - April 22, 2026
BALANCE Model Delay May Lead To Revisions, Higher Near-Term Medicare Costs
Will CMS wait for even lower obesity drug prices before implementing a long-term solution in Medicare?
Generics Bulletin - April 22, 2026
Will CMS wait for even lower obesity drug prices before implementing a long-term solution in Medicare?
Generics Bulletin - April 22, 2026
Amneal’s Bevacizumab Biosimilar Brochure Rebuked By FDA’s OPDP
A brochure for Amneal’s Alymsys biosimilar bevacizumab rival to Avastin has caught the attention of the US Food and Drug Administration’s Office of Prescription Drug Promotion.
Generics Bulletin - April 22, 2026
A brochure for Amneal’s Alymsys biosimilar bevacizumab rival to Avastin has caught the attention of the US Food and Drug Administration’s Office of Prescription Drug Promotion.
Generics Bulletin - April 22, 2026
Steep UK Generic Price Rises Continue In March
While not quite as pronounced as the increases seen in February, the latest UK generic price rises show a continuing trend for multiple molecules to more than double in price.
Generics Bulletin - April 22, 2026
While not quite as pronounced as the increases seen in February, the latest UK generic price rises show a continuing trend for multiple molecules to more than double in price.
Generics Bulletin - April 22, 2026
The Generics Bulletin Podcast: Green Regulations With Medicines for Europe’s Adrian van den Hoven
Generics Bulletin senior reporter Urt? Fultinavi?i?t? speaks to Medicines for Europe’s director general Adrian van den Hoven about pertinent environmental regulation changes in the region.
Generics Bulletin - April 22, 2026
Generics Bulletin senior reporter Urt? Fultinavi?i?t? speaks to Medicines for Europe’s director general Adrian van den Hoven about pertinent environmental regulation changes in the region.
Generics Bulletin - April 22, 2026
Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026
Pharma’s Pipeline Size Dipped In 2025
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026
The 10-80-10 Investment Rule: Preparation Is All
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026